A 506-person retrospective study found that the circulating RNA marker Tu-Stroma distinguished microscopic ovarian-cancer precursor lesions from healthy and benign samples. It detected 92.3% of precursor cases in a validation set, but prospective clinical studies are required before screening or surgical decisions change.